Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Artrya Limited ( (AU:AYA) ) has shared an announcement.
Artrya Limited announced the issuance of 12,500 ordinary shares following the exercise of vested employee performance rights. This move is part of the company’s ongoing efforts to support its operations and enhance its market positioning in the medical technology industry. The issuance of shares reflects Artrya’s commitment to leveraging its workforce’s contributions and aligns with its strategic goals in advancing cardiac care through innovative AI-powered solutions.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company focused on developing AI-powered solutions to enhance the detection and management of coronary artery disease. The company offers a proprietary software that analyzes coronary CT scans to identify key biomarkers of heart disease, aiding clinicians in diagnosing patients more accurately and efficiently. Artrya is committed to advancing cardiac care through innovative technology, with ongoing regulatory and commercial activities in key international markets.
Average Trading Volume: 645,031
Technical Sentiment Signal: Buy
Current Market Cap: A$363M
Learn more about AYA stock on TipRanks’ Stock Analysis page.